These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18454258)

  • 1. Vasoactive hormones and the diabetic kidney.
    Maric C
    ScientificWorldJournal; 2008 Apr; 8():470-85. PubMed ID: 18454258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel effective drugs for diabetic kidney disease? or not?
    Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
    Malek V; Suryavanshi SV; Sharma N; Kulkarni YA; Mulay SR; Gaikwad AB
    Rev Physiol Biochem Pharmacol; 2021; 179():31-71. PubMed ID: 32979084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
    J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.
    Blumenthal SS
    Postgrad Med; 2011 Nov; 123(6):166-79. PubMed ID: 22104465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive renal factors and the progression of diabetic nephropathy.
    Wassef L; Langham RG; Kelly DJ
    Curr Pharm Des; 2004; 10(27):3373-84. PubMed ID: 15544522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin I-converting enzyme: a pathogenetic role in diabetic renal damage?
    Lely AT; Luik PT; Navis G
    Curr Diabetes Rev; 2007 Feb; 3(1):41-52. PubMed ID: 18220655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the renin-angiotensin-aldosterone system: relevance to diabetic nephropathy.
    Koitka A; Tikellis C
    ScientificWorldJournal; 2008 Apr; 8():434-45. PubMed ID: 18454253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the management of special populations: renal disease in diabetes.
    Raij L
    Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
    Kalantarinia K; Okusa MD
    Curr Diab Rep; 2006 Feb; 6(1):8-16. PubMed ID: 16522275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy.
    Nomura H; Kuruppu S; Rajapakse NW
    Front Physiol; 2021; 12():813012. PubMed ID: 35087423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The intrarenal renin-angiotensin system and diabetic nephropathy.
    Carey RM; Siragy HM
    Trends Endocrinol Metab; 2003 Aug; 14(6):274-81. PubMed ID: 12890592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
    J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.